Abstract
Numerous pathophysiological disorders involve some element of oxidative stress and bioenergetic deficit. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors have been used recently as a promising new therapeutic strategy aimed at halting the bioenergetic decline associated with oxidative brain insults and other conditions. PARP-1 uses NAD+ as a substrate and is activated during stressful circumstances, mainly in the nucleus. PARP-1 inhibitors are well known for blocking the excessive consumption of NAD+, thereby preserving energy metabolism. But what is the role of mitochondria in this process? Recent investigations have begun to focus on whether mitochondrial function can also be preserved by PARP-1 inhibitors. This review will present some of the latest mechanistic evidence documenting the potential involvement of PARP-1 inhibitors in protecting mitochondrial function and preventing necrosis, apoptosis and mitochondrial calcium cycling.
Keywords: nicotinamide, poly(adp-ribose) polymerase, mitochondria
Current Medicinal Chemistry
Title: Recent Developments on the Role of Mitochondria in Poly(ADP-ribose) Polymerase Inhibition
Volume: 10 Issue: 24
Author(s): L. K. Klaidman, J. Yang, M. L. Chang and J. D. Adams Jr.
Affiliation:
Keywords: nicotinamide, poly(adp-ribose) polymerase, mitochondria
Abstract: Numerous pathophysiological disorders involve some element of oxidative stress and bioenergetic deficit. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors have been used recently as a promising new therapeutic strategy aimed at halting the bioenergetic decline associated with oxidative brain insults and other conditions. PARP-1 uses NAD+ as a substrate and is activated during stressful circumstances, mainly in the nucleus. PARP-1 inhibitors are well known for blocking the excessive consumption of NAD+, thereby preserving energy metabolism. But what is the role of mitochondria in this process? Recent investigations have begun to focus on whether mitochondrial function can also be preserved by PARP-1 inhibitors. This review will present some of the latest mechanistic evidence documenting the potential involvement of PARP-1 inhibitors in protecting mitochondrial function and preventing necrosis, apoptosis and mitochondrial calcium cycling.
Export Options
About this article
Cite this article as:
Klaidman K. L., Yang J., Chang L. M. and Adams Jr. D. J., Recent Developments on the Role of Mitochondria in Poly(ADP-ribose) Polymerase Inhibition, Current Medicinal Chemistry 2003; 10 (24) . https://dx.doi.org/10.2174/0929867033456323
DOI https://dx.doi.org/10.2174/0929867033456323 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamin D Receptor Agonists: Opportunities and Challenges in Drug Discovery
Current Topics in Medicinal Chemistry Targeting Malignancies with Disulfiram (Antabuse): Multidrug Resistance, Angiogenesis, and Proteasome
Current Cancer Drug Targets Novel Orphan Nuclear Receptors-Coregulator Interactions Controlling Anti-Cancer Drug Metabolism
Current Drug Metabolism Hypoxia-Inducible Factor-1 (HIF-1): A Potential Target for Intervention in Ocular Neovascular Diseases
Current Drug Targets Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
Current Pharmaceutical Design Structure-based Virtual Screening for the Identification of High-affinity Small Molecule Towards STAT3 for the Clinical Treatment of Osteosarcoma
Current Topics in Medicinal Chemistry Imaging Virus-Associated Cancer
Current Pharmaceutical Design Potential Lithium and Fluoride Interactions in Studies of Glycogen Synthase Kinase-3
Current Enzyme Inhibition Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design Macroautophagy as a Target of Cancer Therapy
Current Cancer Therapy Reviews Targeting RhoA/Rho Kinase and p21-Activated Kinase Signaling to Prevent Cancer Development and Progression
Recent Patents on Anti-Cancer Drug Discovery Aurora Kinase Inhibitors in Head and Neck Cancer
Current Topics in Medicinal Chemistry 2-Deoxy-D-Ribose, a Downstream Mediator of Thymidine Phosphorylase, Regulates Tumor Angiogenesis and Progression
Anti-Cancer Agents in Medicinal Chemistry Decreased lncRNA SNHG16 Accelerates Oxidative Stress Induced Pathological Angiogenesis in Human Retinal Microvascular Endothelial Cells by Regulating miR-195/mfn2 Axis
Current Pharmaceutical Design The Early Bird Catches the Worm – Can Evolution Teach us Lessons in Fighting HIV?
Current HIV Research Mitochondrial Thymidine Kinase Inhibitors
Current Topics in Medicinal Chemistry Exploring Proteomic Drug Targets, Therapeutic Strategies and Protein - Protein Interactions in Cancer: Mechanistic View
Current Cancer Drug Targets The Roles of Parathyroid Hormone and Calcitonin in Bone Remodeling: Prospects for Novel Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets NF-κB Decoy Oligodeoxynucleotides Inhibits Kupffer Cell Activation
Current Signal Transduction Therapy Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry